tbuckley/cabot-search huggingface dataset:
Cemiplimab, a human PD-1 monoclonal antibody, in patients (pts) with recurrent or metastatic cervical cancer: Interim data from phase I cohorts
Authors: D. Rischin, M. Gil-Martin, A. González-Martín, I. Brana, J.Y. Hou, D. Cho, G.S. Falchook, S. Formenti, S. Jabbour, K. Moore, A. Naing, K.P. Papadopoulos, J. Baranda, A. Weise, M.G. Fury, M. Feng, J. Li, I. Lowy, M. Mathias
Journal: Annals of Oncology (2018)
P2.11-09 Uncommon EGFR Mutation Analysis from Urine of Lung Cancer Patients
Authors: P. Hikmawati, F. Fadiyah, F. Patria, A. Ridwanuloh, A. Hudoyo, J. Zaini, S. Andarini, A. Utomo
Journal: Journal of Thoracic Oncology (2018)
Exploratory analyses of 400 patients enrolled in 2 FFCD trials of first line treatment for metastatic pancreatic cancer
Authors: J. Taieb, J.M. Phelip, Y. Rinaldi, E. Barbier, O. Bouche, F. Khemissa Akouz, A. Gratet, C. Petorin, L. Miglianico, D. Malka, H. Laharie Mineur, C. Rebischung, C. Lepage, E. Francois, L. Dahan
Journal: Annals of Oncology (2018)
P1.01-25 Carboplatin and Pemetrexed Plus Bevacizumab After Failure of First-Line EGFR-TKI Therapy for NSCLC Harboring EGFR Mutation (CJLSG 0908)
Authors: Y. Goto, K. Takahashi, H. Saito, T. Ogasawara, J. Shindoh, T. Kimura, Y. Sugino, E. Kojima, F. Nomura, T. Nakanishi, Y. Nozaki, Y. Takeyama, K. Imaizumi, Y. Hasegawa
Journal: Journal of Thoracic Oncology (2018)
ABCB1 genetic polymorphism and pharmacokinetic analysis of low dose erlotinib in frail patients with EGFR mutation (mt)-positive, non-small cell lung cancer: TORG1425
Authors: S. Miyamoto, T. Tokkito, A. Bessho, N. Fukamatsu, H. Kunitoh, M. Ishii, H. Tanaka, H. Aono, T. Fukui, K. Kusaka, Y. Hosomi, A. Hamada, K. Yamada, H. Okamoto
Journal: Annals of Oncology (2018)
MEDIOLA: A phase I/II trial of olaparib (PARP inhibitor) in combination with durvalumab (anti-PD-L1 antibody) in pts with advanced solid tumours – new ovarian cancer cohorts
Authors: R.T. Penson, Y. Drew, M.J.A. de Jonge, S.-H. Hong, Y.H. Park, A. Wolfer, J. Brown, M. Ferguson, M.E. Gore, R.H. Alvarez, B. Kaufman, C. Gresty, H.K. Angell, K. Meyer, M. Lanasa, P. Herbolsheimer, S. Domchek
Journal: Annals of Oncology (2018)
Interim results from a real world European survey on the unmet needs of patients living with metastatic colorectal cancer (mCRC)
Authors: Z. Maravic, J.M. Borras, E. Espin Basany, Á Petrányi, Z. Kapitany, P. Rakonczai, A. Benedict, N. Muszbek
Journal: Annals of Oncology (2018)
Characteristics of the psychosomatic state of patients with lung cancer
Authors: G. Zhukova, A.I. Shikhlyarova, E. Shirnina, M. Zinkovich, N. Maschenko, E. Zlatnik, S. Pyltsin, P. Anistratov, M.I. Bragina, A. Zhadobina, L.Y. Vladimirova
Journal: Annals of Oncology (2018)
P2.01-52 Identification of Leptomeningeal Metastasis-Specific Exosomal miRNA Signatures in Cerebrospinal Fluids of NSCLC Patients
Authors: B. Jiang, Y. Li, X. Wu, B. Hua, Y. Ding, J.-. Yang, X. Zhang, X. Yang, W. Zhong, Q. Zhou, H. Tu, C.Y. Gao, S. Wu, Y.W. Shao, Y. Wu
Journal: Journal of Thoracic Oncology (2018)
P1.13-06 First-Line Lorlatinib Versus Crizotinib for Advanced Anaplastic Lymphoma Kinase-Positive (ALK+) Non-Small Cell Lung Cancer
Authors: A. Shaw, T. Bauer, T. Takahashi, C. Baik, Y. Goto, A. Polli, M. Carpentieri, J. Martini, B. Solomon
Journal: Journal of Thoracic Oncology (2018)
High-Flow Nasal Oxygen—The Pendulum Continues to Swing in the Assessment of Critical Care Technology
Authors: Karen C. Dugan, Jesse B. Hall, Bhakti K. Patel
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Long-term Efficacy of Tenofovir Disoproxil Fumarate Monotherapy for Multidrug-Resistant Chronic HBV infection
Authors: Hye Won Lee, Jun Yong Park, Jin Woo Lee, Ki Tae Yoon, Chang Wook Kim, Hana Park, Young Seok Kim, Soon Ku Paik, Jung Il Lee, Beom Kyung Kim, Kwang-Hyub Han, Sang Hoon Ahn
Journal: Clinical Gastroenterology and Hepatology (2018)
P2.04-24 Nivolumab in the "Real World": Are the Results of Clinical Trials Reproducible?
Authors: I. Ramos García, A. Sanchez Gastaldo, I. Barneto, P. Ayala, M. Berciano, R. Bernabé, M. Robles, R. Collado, M. Alonso, T. García, M. Cobo Dols, J.M. Trigo
Journal: Journal of Thoracic Oncology (2018)
P1.04-21 The Utility of PD-L1/CD8 Dual Immunohistochemistry for Prediction of Response to Immunotherapy in Non-Small Cell Lung Cancer (NSCLC)
Authors: M. Rosenbaum, S. Khosrowjerdi, V. Kamesan, S. Digumarthy, J. Gainor, M. Mino-Kenudson
Journal: Journal of Thoracic Oncology (2018)
P1.12-07 Time to the End of Thoracic Radiotherapy Affects to Survival Outcomes Greater than Radiation Dose in Limited Stage Small Cell Lung Cancer
Authors: S. Ahn, J. Jeong, W. Jeon, Y. Kim, I. Oh, C. Park, M.S. Yoon, J. Song, T. Nam, W. Chung
Journal: Journal of Thoracic Oncology (2018)
MA13.02 PD-L1 Expression in EBUS-Guided Cytology Specimens of Non-Small Cell Lung Cancer is Not Affected by Type of Fixation: A Study of Matched Pairs
Authors: J. Gosney, A. Haragan, C. Chadwick, T. Giles, S. Grundy, V. Tippett, K. Gumparthy, A. Wight, H. Tan
Journal: Journal of Thoracic Oncology (2018)
Homology-directed repair (HDR)-defective lung adenocarcinomas (LUACs) in circulating tumor DNA (ctDNA)
Authors: N. Karachaliou, M. Lefterova, J.F. Draper, M.-A. Molina, I. Chaib, R. Palmero, A. Taus, S. Viteri, M. González Cao, M. Majem Tarruella, E. Carcereny Costa, T. Moran, J. Garde Noguera, E. Felip Font, S. Olsen, M. Jackson, M. Sampayo, I. Faull, D. Dix, R. Rosell
Journal: Annals of Oncology (2018)
Abstract 18948: Galectin-3 as a Novel Biomarker of Unstable Coronary Plaque
Authors: Amrit Bajrangee, Shanti Mahabir, Leah Arkins, Cormac Oconnor, Ana Lopez Alonso, Marian Brennan, Dermot Cox, Andrew Maree
Journal: Circulation (2016)

Introduction: Galectin-3 (Gal-3) is a pleiotropic lectin that is upregulated when monocytes differentiate into macrophages. It plays an important role in cell proliferation, angiogenesis and apopto...
Phase II study of CC-486 in previously treated patients (pts) with locally advanced/metastatic nasopharyngeal cancer (NPC): Final results
Authors: R. Mesia Nin, P. Bossi, A. Hansen, C. Hsieh, L.F. Licitra, E.H. Tan, P. Chen, J. Miller, L.L. Siu, R. Haddad
Journal: Annals of Oncology (2018)
Dynamics of immune checkpoint molecule (ICM) expression in immune cell subsets during curative conventional therapy of head and neck squamous cell carcinoma (HNSCC)
Authors: A. Grages, S.S. Jeske, L.K. Puntigam, C. Brunner, J. Kraus, H. Kestler, J. Döscher, T.K. Hoffmann, P.J. Schuler, S. Laban
Journal: Annals of Oncology (2018)
Relationship between immune related molecules and chemosensitivity and prognosis in gastric cancer
Authors: T. Hagi, Y. Kurokawa, T. Hashimoto, Y. Miyazaki, T. Takahashi, K. Tanaka, T. Makino, M. Yamasaki, K. Nakajima, M. Mori, Y. Doki
Journal: Annals of Oncology (2018)
TOPNIVO: A safety study of nivolumab in patients with recurrent and/or metastatic platinum-refractory squamous cell carcinoma of the head and neck (R/M SCCHN): First results on behalf of the UNICANCER Head&amp;Neck Group and the GORTEC
Authors: C. Even, A. Daste, E. Saada-Bouzid, J. Fayette, M.-C. Kaminsky-Forrett, S. Zanetta, A. Prevost, G. Lefebvre, C. Borel, D. Cupissol, F. Huguet, J.-P. Delord, N. Baste Rotllan, J. Delaye, I. Jallut, N. Vintonenko, J. Bourhis, J. Guigay, M. Texier, A. Auperin
Journal: Annals of Oncology (2018)
P2.17-07 Concurrent Chemoradiotherapy (ConCRT) using Cisplatin-Vinorelbine in Locally Advanced (LA) Non-Small Cell Lung Cancer (NSCLC)
Authors: H. Charalambous, I. Constantinou, D. Vomvas, N. Katodritis, G. Orphanos, F. Kyriacou, I. Porfiridis, M. Decatris
Journal: Journal of Thoracic Oncology (2018)
Characterizing the risk of drug-drug interactions in sarcoma treated patients: Role of pharmacist integration
Authors: A. Bellesoeur, I. Gataa, A. Jouinot, S. El Mershati, J. Arrondeau, C. Tlemsani, B. Blanchet, J. Alexandre, F. Goldwasser, A. Thomas-Schoemann, P. Boudou Rouquette
Journal: Annals of Oncology (2018)
Genetic testing of BRCA mutations in breast cancer in six European countries: Barriers and opportunities
Authors: M. Thrift-Perry, S. Ahmed, S. Wait, J. Tate
Journal: Annals of Oncology (2018)

Background: Mutations in BRCA1 and BRCA2 are linked to 5–10% of breast cancer cases, often resulting in worse outcomes than non-hereditary cases. Across Europe, genetic testing and optimal management of BRCA mutation carriers face a number of barriers. Methods: We developed seven country profiles: France, Germany, Ireland, Israel, Italy, Sweden and UK. We examined barriers and opportunities in the policy landscape; guideline and testing criteria; advocacy efforts; access to genetic testing and counselling and ongoing support and protection. The profiles were based on pragmatic literature review and qualitative interviews with national level experts including health professionals, researchers and patient representatives. Results: Preliminary findings currently being verified by the experts include: Oncogenetic testing is integrated in few national (breast) cancer policies, but all selected countries have criteria for BRCA genetic testing. Some countries, e.g. Ireland and Sweden, have stricter eligibility criteria, limiting access. BRCA-related advocacy activities seem sparse. However, demand for genetic testing has soared. In France for example, the number of women tested increased fivefold between 2003 and 2016. Genetic BRCA testing is free of charge in all selected countries except Italy, where it is only free in certain regions. However, women still may face long wait times and geographical inequalities in service provision due to a lack of appropriately trained healthcare professionals. In three of the selected countries, genetic counselling is not mandatory and in many countries availability of genetic counsellors is low, creating a bottleneck to service provision. Conclusions: This research identified opportunities and recommendations for patients and policymakers to understand what is needed to ensure European women who may be at risk of carrying BRCA mutations can access and utilise high quality services along the whole patient journey. Legal entity responsible for the study: The Health Policy Partnership. Funding: Pfizer Inc. Disclosure: M. Thrift-Perry: Employee: Pfizer Inc.; Supported the Health Policy Partnership research: Pfizer Inc. All other authors have declared no conflicts of interest.
Role of evaluating tumor infiltrating lymphocytes, programmed death-ligand 1 and mismatch-repair proteins expression in malignant mesothelioma
Authors: L. Losi, F. Bertolini, L. Scurani, G. Guaitoli, C. Baldessari, A. Ambrosini Spaltro, L. Botticelli, A. Maiorana, F. Barbieri, S. Cascinu
Journal: Annals of Oncology (2018)
P2.16-50 Do Patients Have Preconceived Ideas on Various Surgical Approaches? Patient Perspective: Open vs. Minimally Invasive Surgery (PROMIS) Survey
Authors: C. Yeung, A. Martel, M. Hanna, A. Moledina, A. Seely, D. Maziak, F. Shamji, S. Sundaresan, P. Villeneuve, S. Gilbert
Journal: Journal of Thoracic Oncology (2018)
Tracking VSV-IFNβ-NIS oncolytic virus (OV) activity in patients (pts) with advanced solid tumors: The iodide symporter gene (NIS) as a pharmacodynamic (PD) marker using SPECT/CT imaging of OV therapy
Authors: J. Merchan, M.R. Patel, S.F. Powell, J. Strauss, T.P. Cripe, M.O. Old, R.M. Diaz, S.J. Russell, A.S. Bexon, L. Suksanpaisan, M.K. O’Connor, K.W. Peng
Journal: Annals of Oncology (2018)
P3.01-24 The Importance to Switch from EGFR-TKI to Cytotoxic Chemotherapy for EGFR Mutation-Positive Adenocarcinoma
Authors: D. Eriguchi, T. Okano, Y. Kawaguchi, J. Maeda, M. Hagiwara, M. Kakihana, N. Kajiwara, T. Ohira, N. Ikeda
Journal: Journal of Thoracic Oncology (2018)
Nab-paclitaxel (nab-P) in metastatic breast cancer (MBC) in elderly patients: A real life setting (NEREIDE study)
Authors: V. Adamo, G.R.R. Ricciardi, S. Schifano, A. Russo, V. Gebbia, L. Blasi, D. Giuffrida, G. Scandurra, A. Savarino, A. Butera, N. Borsellino, F. Verderame, M. Caruso
Journal: Annals of Oncology (2018)
Cyclin D1 differential activation and its prognostic impact among advanced breast cancer patients treated with trastuzumab
Authors: G. Mountzios, V. Kotoula, G.-A. Koliou, K. Papadopoulou, G. Lazaridis, C. Christodoulou, G. Pentheroudakis, M. Skondra, A. Koutras, H. Linardou, E. Razis, P. Papakostas, S. Chrisafi, G. Aravantinos, I. Nicolaou, A. Goussia, K.T. Kalogeras, D.G. Pectasides, G. Fountzilas
Journal: Annals of Oncology (2018)
P1.01-55 Unique Genetic Profiles from Cerebrospinal Fluid Could Predict Survival of EGFR-Mutant NSCLC with Leptomeningeal Metastases
Authors: Y. Li, B. Jiang, M. Zheng, H. Tu, J.-. Yang, X. Zhang, J. Ye, Q. Zhou, W. Zhong, C. Zhang, S. Chuai, Y. Wu
Journal: Journal of Thoracic Oncology (2018)
P2.04-16 Correlation Between Programmed Death Ligand 1(PD-L1) Expression and Solid Component on HRCT in Stage I Lung Cancer Patients
Authors: R. Tsugitomi, N. Nishimura, H. Kanemra, R. Imai, N. Yoshiyasu, K. Okafuji, A. Kitamura, Y. Tomishima, F. Kojima, T. Jinta, K. Suzuki, T. Bando, T. Tamura
Journal: Journal of Thoracic Oncology (2018)
<i>Salmonella</i>exploits HLA-B27 and host unfolded protein responses to promote intracellular replication
Authors: Antony Nicodemus Antoniou, Izabela Lenart, Janos Kriston-Vizi, Takao Iwawaki, Mark Turmaine, Kirsty McHugh, Sadfer Ali, Neil Blake, Paul Bowness, Mona Bajaj-Elliott, Keith Gould, Darren Nesbeth, Simon J Powis
Journal: Annals of the Rheumatic Diseases (2018)

Objective Salmonella enterica infections can lead to Reactive Arthritis (ReA), which can exhibit an association with human leucocyte antigen (HLA)-B*27:05, a molecule prone to misfolding and initiation of the unfolded protein response (UPR). This study examined how HLA-B*27:05 expression and the UPR affect the Salmonella life-cycle within epithelial cells. Methods Isogenic epithelial cell lines expressing two copies of either HLA-B*27:05 and a control HLA-B*35:01 heavy chain (HC) were generated to determine the effect on the Salmonella infection life-cycle. A cell line expressing HLA-B*27:05.HC physically linked to the light chain beta-2-microglobulin and a specific peptide (referred to as a single chain trimer, SCT) was also generated to determine the effects of HLA-B27 folding status on S. enterica life-cycle. XBP-1 venus and AMP dependent Transcription Factor (ATF6)-FLAG reporters were used to monitor UPR activation in infected cells. Triacin C was used to inhibit de novo lipid synthesis during UPR, and confocal imaging of ER tracker stained membrane allowed quantification of glibenclamide-associated membrane. Results S. enterica demonstrated enhanced replication with an altered cellular localisation in the presence of HLA-B*27:05.HC but not in the presence of HLA-B*27:05.SCT or HLA-B*35:01. HLA-B*27:05.HC altered the threshold for UPR induction. Salmonella activated the UPR and required XBP-1 for replication, which was associated with endoreticular membrane expansion and lipid metabolism. Conclusions HLA-B27 misfolding and a UPR cellular environment are associated with enhanced Salmonella replication, while Salmonella itself can activate XBP-1 and ATF6. These data provide a potential mechanism linking the life-cycle of Salmonella with the physicochemical properties of HLA-B27 and cellular events that may contribute to ReA pathogenesis. Our observations suggest that the UPR pathway maybe targeted for future therapeutic intervention.
MA15.11 Real World Biomarker Testing and Treatment Patterns in Patients with Advanced NSCLC Receiving EGFR-TKIs
Authors: A. Chiang, A. Fernandes, M. Pavilack, J. Wu, F. Laliberté, M.S. Duh, N. Chehab, J. Subramanian
Journal: Journal of Thoracic Oncology (2018)
A randomized, open-label, non-inferiority study comparing the efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B-cell non-Hodgkin lymphomas (B-NHL): AVOID neutropenia
Authors: H. Link, G. Illerhaus, U.M. Martens, A. Salar, R. Depenbusch, A. Kohler, M.M. Engelhardt, S. Mahlmann, M. Zaiss, A. Lammerich, P. Bias, A. Buchner
Journal: Annals of Oncology (2018)
Woodpeckers don’t play football: implications for novel brain protection devices using mild jugular compression
Authors: James M Smoliga, Lizhen Wang
Journal: British Journal of Sports Medicine (2018)

As sports concussions and chronic traumatic encephalopathy have captured the media’s attention, sports organisations and athletes have become increasingly interested in novel approaches to reduce brain injury risk. One proposal is to protect the brain from within by decreasing brain ‘slosh’. This can supposedly be achieved by creating a ‘tighter fit’ of the brain within the skull.1 Woodpeckers are often cited as model organisms for achieving this,1 and one emerging device claims to replicate the woodpecker’s mechanism for protecting its brain.2 This device is a collar worn around the neck which compresses the jugular veins, known as the Q-collar or  Neuroshield (www.q30innovations.com and www.neuroshield.ca). Unfortunately, this woodpecker-inspired concept is misguided for numerous reasons (see online supplementary file 1 for additional references).

1.  Woodpeckers have multiple evolutionary adaptations to protect their brains. Computed tomography has confirmed that woodpeckers have numerous microstructural adaptations within the skull, including regionally specific alterations in trabecular bone morphology, which provide favourable mechanical properties.3 The woodpecker’s unique hyoid bone and tongue structure dissipate shock.3 4 Additionally, the woodpecker’s beak is highly specialised, with …
Platelet Serotonin Aggravates Myocardial Ischemia/Reperfusion Injury via Neutrophil Degranulation
Authors: Maximilian Mauler, Nadine Herr, Claudia Schoenichen, Thilo Witsch, Timoteo Marchini, Carmen Härdtner, Christoph Koentges, Korbinian Kienle, Véronique Ollivier, Maximilian Schell, Ludwig Dorner, Christopher Wippel, Daniela Stallmann, Claus Normann, Heiko Bugger, Paul Walther, Dennis Wolf, Ingo Ahrens, Tim Lämmermann, Benoît Ho-Tin-Noé, Klaus Ley, Christoph Bode, Ingo Hilgendorf, Daniel Duerschmied
Journal: Circulation (2019)

Background: Platelets store large amounts of serotonin that they release during thrombus formation or acute inflammation. This facilitates hemostasis and modulates the inflammatory response. Methods: Infarct size, heart function, and inflammatory cell composition were analyzed in mouse models of myocardial reperfusion injury with genetic and pharmacological depletion of platelet serotonin. These studies were complemented by in vitro serotonin stimulation assays of platelets and leukocytes in mice and men, and by measuring plasma serotonin levels and leukocyte activation in patients with acute coronary syndrome. Results: Platelet-derived serotonin induced neutrophil degranulation with release of myeloperoxidase and hydrogen peroxide (H 2 O 2 ) and increased expression of membrane-bound leukocyte adhesion molecule CD11b, leading to enhanced inflammation in the infarct area and reduced myocardial salvage. In patients hospitalized with acute coronary syndrome, plasmatic serotonin levels correlated with CD11b expression on neutrophils and myeloperoxidase plasma levels. Long-term serotonin reuptake inhibition—reported to protect patients with depression from cardiovascular events—resulted in the depletion of platelet serotonin stores in mice. These mice displayed a reduction in neutrophil degranulation and preserved cardiac function. In line, patients with depression using serotonin reuptake inhibition, presented with suppressed levels of CD11b surface expression on neutrophils and lower myeloperoxidase levels in blood. Conclusions: Taken together, we identify serotonin as a potent therapeutic target in neutrophil-dependent thromboinflammation during myocardial reperfusion injury.
P1.13-23 TP53 Mutations as Mechanisms of Primary and Acquired Resistance to Tyrosine Kinase Inhibitors in Patients With EGFR-Mutated NSCLC
Authors: M. Canale, V. Ludovini, L. Crinò, C. Dazzi, E. Chiadini, L. Capelli, M. Papi, M. Mariotti, N. De Luigi, G. Minuti, D. Calistri, S. Baglivo, R. Chiari, M. Bonafè, A. Delmonte, P. Ulivi
Journal: Journal of Thoracic Oncology (2018)
MA04.11 Neoantigen Targeting and T Cell Reshaping in Resectable NSCLC Patients Treated with Neoadjuvant PD-1 Blockade
Authors: M. El Asmar, J. Zhang, J. Caushi, Z. Ji, V. Anagnostou, T. Cottrell, H.Y. Chan, P. Suri, H. Guo, K. Marrone, J. Naidoo, T. Merghoub, J. Chaft, M. Hellmann, J. Taube, J. Brahmer, P. Forde, V. Velculescu, D. Pardoll, H. Ji, K. Smith
Journal: Journal of Thoracic Oncology (2018)
Phase II study of tepotinib + gefitinib (TEP+GEF) in MET-positive (MET+)/epidermal growth factor receptor (EGFR)-mutant (MT) non-small cell lung cancer (NSCLC)
Authors: Y. Cheng, J. Zhou, S. Lu, Y. Zhang, J. Zhao, H. Pan, Y.-M. Chen, C.-F. Chian, R. Bruns, A. Johne, J. Scheele, Y.-L. Wu
Journal: Annals of Oncology (2018)